LAM was equally likely to be treated with an mTOR inhibitor with a similar benefit in preventing loss of FEV1 and DLCO although an additional 17% of TSC-LAM patients were receiving an mTOR inhibitor primarily for angiomyolipoma rather than LAM. Here, MTOR is linked to lymphangioleiomyomatosis.